General
Preferred name
DIACEREIN
Synonyms
DIACERIN ()
2-Anthracenecarboxylic acid, 4,5-bis(acetyloxy)-9,10-dihydro-9,10-dioxo- ()
Diacerhein ()
Fisiodar ()
Diacetylrhein ()
diacerein (capsule), TWi Pharmaceuticals ()
1,8-Diacetoxy-3-carboxyanthraquinone ()
Verboril ()
Zondar ()
Diacereine ()
SF-277 ()
Rhein diacetate ()
AC-201 ()
Diacereina ()
Artrodar ()
Diora ()
NSC-758147 ()
M01AX21 ()
Ac-203 ()
M-01AX21 ()
P&D ID
PD001435
CAS
13739-02-1
112118-18-0
Tags
available
drug
Drug Status
approved
investigational
Max Phase
3.0
Drug indication
rheumatic disease
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Diacerein is a prodrug which is metabolized to rhein. It has anti-inflammatory activity via antagonism of the interleukin-1 receptor. It is an anthraquinone type compound and growth-inhibitory effects of diacerein have been shown against various drug-resistant staphylococcal strains .
(GtoPdb)
DESCRIPTION
Diacerein (Diacerhein), an orally active anthraquinone, reduces production of IL-1 converting enzyme then inhibits the activation of IL-1¦Â by related downstream signaling. Diacerein is an anti-inflammatory and anti-rheumatic drug. Diacerein can relieve bronchospasm and control airway inflammation in asthmatic mice. Diacerein has the potential for slow acting drug in osteoarthritis (SYSADOA) research[1][2][3].
PRICE
29
DESCRIPTION
Diacerin is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Diacerein (Fisiodar) is a prodrug which is metabolized to rhein. It is currently approved in France for the treatment of osteoarthritis although the use of diacerein is restricted due to the side effects including sevre diarrhea [L780]. Diacerein is under investigation for the treatment of Insulin Resistance, Diabetes Mellitus (Type 2), and Diabetes-Related Complications.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
1
Organisms
0
Compound Sets
23
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Drugs
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
Guide to Pharmacology
JUMP-Target 1 Compound Set
LSP-MoA library (Laboratory of Systems Pharmacology)
Mcule NIBR MoA Box Subset
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
37
Molecular Weight
368.05
Hydrogen Bond Acceptors
7
Hydrogen Bond Donors
1
Rotatable Bonds
3
Ring Count
3
Aromatic Ring Count
2
cLogP
2.01
TPSA
124.04
Fraction CSP3
0.11
Chiral centers
0.0
Largest ring
6.0
QED
0.55
Structural alerts
1
quinone_A(370)
[!#6&!#1]=[#6]1[#6]=,:[#6][#6](=[!#6&!#1])[#6]=,:[#6]1
PAINS Family A
Related compounds
Custom attributes
(extracted from source data)
Target
IL-1β
Interleukin
IL1B
Calcium Channel
Interleukin Related
Interleukins
Member status
member
MOA
IL-1 Inhibitors
interleukin inhibitor
Indication
osteoarthritis
Pathway
Immunology/Inflammation
Membrane Transporter/Ion Channel
Neuronal Signaling
Source data
